Abstract: An inverted nanocone structure of the present disclosure includes a first surface, a second surface spaced apart from the first surface by a predetermined distance and having a greater area than the first surface, and a body having an inverted cone shape between the first surface and the second surface, wherein at least one activated point defect center is provided in the body.

Abstract: This specification discloses a quantum public-key cryptosystem. The quantum public-key cryptosystem may use two rotation operators R{circumflex over (n)}(?) and R{circumflex over (m)}(?) satisfying a cyclic evolution. The two rotation operators R{circumflex over (n)}(?) and R{circumflex over (m)}(?) do not have a commutation relation or an anti-commutation relation with each other. The commutation relation or the anti-commutation relation is established when either of the following conditions is satisfied: ?=2i?, ?=2j?, or {circumflex over (n)}·{circumflex over (m)}=1 (i, j=integer), and ?=(2k+1)?, ?=(2l+1)?, or {circumflex over (n)}·{circumflex over (m)}=0 (k, l=integer).

Abstract: An inverted nanocone structure of the present disclosure includes a first surface, a second surface spaced apart from the first surface by a predetermined distance and having a greater area than the first surface, and a body having an inverted cone shape between the first surface and the second surface, wherein at least one activated point defect center is provided in the body.

Abstract: This specification discloses a quantum public-key cryptosystem. The quantum public-key cryptosystem may use two rotation operators R{circumflex over (n)}(?) and R{circumflex over (m)}(?) satisfying a cyclic evolution. The two rotation operators R{circumflex over (n)}(?) and R{circumflex over (m)}(?) do not have a commutation relation or an anti-commutation relation with each other. The commutation relation or the anti-commutation relation is established when either of the following conditions is satisfied: ?=2i?, ?=2j?, or {circumflex over (n)}·{circumflex over (m)}=1 (i, j=integer), and ?=(2k+1)?, ?=(2l+1)?, or {circumflex over (n)}·{circumflex over (m)}=0 (k, l=integer).

Abstract: The present invention relates to a bacteriophage having a specific bactericidal activity against Salmonella, a composition for the prevention or treatment of infectious diseases comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, an animal feed or drinking water comprising the bacteriophage as an active ingredient, and a sanitizer or cleaner comprising the bacteriophage as an active ingredient. The bacteriophage of the present invention has a specific bactericidal activity against Salmonella choleraesuis, Salmonella typhimurium, Salmonella derby, Salmonella infantis or Salmonella newport with no influences on beneficial bacteria, as well as excellent acid- and heat-resistance and desiccation tolerance.

Abstract: The present invention relates to a bacteriophage having a specific bactericidal activity against Salmonella, a composition for the prevention or treatment of infectious diseseases comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, an animal feed or drinking water comprising the bacteriophage as an active ingredient, and a sanitizer or cleaner comprising the bacteriophage as an active ingredient. The bacteriophage of the present nvention has a specific bactericidal activity against Salmonella choleraesuis, Salmonella typhimurium, Salmonella derby, Salmonella infantis, or Salmonella newport with no influences on beneficial bacteria, as well as excellent acid- and heat-resistance and desiccation tolerance.

Abstract: The present invention relates to a novel bacteriophage having a specific bactericidal activity against salmonella, a composition for the prevention or treatment of infectious diseases comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, an animal feed or drinking water comprising the bacteriophage as an active ingredient, and a sanitizer or cleaner comprising the bacteriophage as an active ingredient. The novel bacteriophage of the present invention has a specific bactericidal activity against Salmonella choleraesuis, Salmonella typhimurium, Salmonella derby, Salmonella infantis or Salmonella newport with no influences on beneficial bacteria, as well as excellent acid- and heat-resistance and desiccation tolerance.

Abstract: Described herein are microorganisms that produce methionine and related products from endogenous genes in a transsulfuration pathway, as well as from exogenous genes providing a direct sulfhydrylation pathway. Novel genes that are useful for methionine and SAMe production are disclosed.

Abstract: The present invention relates to a novel bacteriophage having an E. coli-specific bactericidal activity, a composition for the prevention or treatment of infectious diseases caused by Enterotoxigenic E. coli comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, a feed additive composition comprising the bacteriophage as an active ingredient, a sanitizer or cleaner comprising the bacteriophage as an active ingredient, and a method for treating colibacillosis using the bacteriophage. The novel bacteriophage of the present invention has a specific bactericidal activity against pathogenic E. coli, and excellent acid- and heat-resistance. Therefore, the novel bacteriophage can be used for the prevention or treatment of swine colibacillosis, which is an infectious disease caused by pathogenic E. coli, and can also be widely used in animal feed additive compositions, sanitizers, and cleaners.

Abstract: Described herein are microorganisms that produce methionine and related products from endogenous genes in a transsulfuration pathway, as well as from exogenous genes providing a direct sulfhydrylation pathway. Novel genes that are useful for methionine and SAMe production are disclosed.

Abstract: The present invention relates to avirulent Salmonella Gallinarum variants by inactivating virulence gene clusters of Salmonella Gallinarum (SG), a main pathogen of avian salmonellosis, and various uses thereof notably in the production of Salmonella-specific lytic bacteriophages, pharmaceutical compositions and feed additives.

Abstract: Described herein are microorganisms that produce methionine and related products from endogenous genes in a transsulfuration pathway, as well as from exogenous genes providing a direct sulfhydrylation pathway. Novel genes that are useful for methionine and SAMe production are disclosed.

Abstract: The present invention relates to a method for producing L-methionine, comprising: i) culturing an L-methionine precursor-producing microorganism strain in a fermentation solution, so that the L-methionine precursor accumulates in the solution; and ii) mixing a converting enzyme and methylmercaptan or its salts with at least a portion of the solution to convert the accumulated L-methionine precursor into L-methionine, as well as to microorganism strains used in each step.

Abstract: The present invention relates to a method for producing L-methionine, comprising: i) culturing an L-methionine precursor-producing microorganism strain in a fermentation solution, so that the L-methionine precursor accumulates in the solution; and ii) mixing a converting enzyme and methylmercaptan or its salts with at least a portion of the solution to convert the accumulated L-methionine precursor into L-methionine, as well as to microorganism strains used in each step.

Abstract: The present invention relates to a microorganism producing L-methionine precursor, O-acetylhomoserine, and a method of producing L-methionine precursor using the microorganism.

Abstract: The present invention relates to a novel bacteriophage having an E.-coli-specific bactericidal activity, a composition for the prevention or treatment of infectious diseases caused by Enterotoxigenic E.-coli comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, a feed additive composition comprising the bacteriophage as an active ingredient, a sanitizer or cleaner comprising the bacteriophage as an active ingredient, and a method for treating colibacillosis using the bacteriophage. The novel bacteriophage of the present invention has a specific bactericidal activity against pathogenic E. coli, and excellent acid- and heat-resistance. Therefore, the novel bacteriophage can be used for the prevention or treatment of swine colibacillosis, which is an infectious disease caused by pathogenic E.-coli, and can also be widely used in animal feed additive compositions, sanitizers, and cleaners.

Abstract: The present invention relates to a novel bacteriophage having a specific bactericidal activity against salmonella, a composition for the prevention or treatment of infectious diseases comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, an animal feed or drinking water comprising the bacteriophage as an active ingredient, and a sanitizer or cleaner comprising the bacteriophage as an active ingredient. The novel bacteriophage of the present invention has a specific bactericidal activity against Salmonella choleraesuis, Salmonella typhimurium, Salmonella derby, Salmonella infantis or Salmonella newport with no influences on beneficial bacteria, as well as excellent acid- and heat-resistance and desiccation tolerance.

Abstract: Disclosed herein is a novel bacteriophage which has specific bactericidal activity against one or more Salmonella bacteria selected from the group consisting of Salmonella enteritidis, Salmonella typhimurium, Salmonella gallinarum, and Salmonella pullorum without affecting beneficial bacteria, in addition to showing excellent tolerance to acid, heat and desiccation. The novel bacteriophage of the present invention can be widely used as an active ingredient for therapeutic agents, animal feeds or drinking water, cleaners and sanitizers for preventing and treating the infectious diseases caused by Salmonella enteritidis, Salmonella typhimurium, Salmonella gallinarum or Salmonella pullorum including salmonellosis, Salmonella food poisoning, Fowl Typhoid, and Pullorum disease or for controlling the Salmonella bacteria.

Abstract: The present invention relates to a novel bacteriophage, more particularly, a bacteriophage that has a specific bactericidal activity against Salmonella typhimurium, Salmonella gallinarum, or Salmonella pullorum, a composition for the prevention or treatment of infectious diseases including salmonellosis and Salmonella food poisoning caused by Salmonella typhimurium, Fowl typhoid caused by Salmonella gallinarum, and Pullorum disease caused by Salmonella pullorum, which comprises the bacteriophage as an active ingredient, and an animal feed, drinking water, cleaner, and sanitizer which comprise the bacteriophage as an active ingredient. The present invention also provides important insights into prevention and control strategies against Salmonella infection and suggests that the use of bacteriophage can be a novel, safe, and effectively plausible alternative to antibiotics for the prevention of Salmonella infection in poultry.

Abstract: Disclosed herein is a novel bacteriophage which has specific bactericidal activity against one or more Salmonella bacteria selected from the group consisting of Salmonella enteritidis, Salmonella typhimurium, Salmonella gallinarum, and Salmonella pullorum without affecting beneficial bacteria, in addition to showing excellent tolerance to acid, heat and desiccation. The novel bacteriophage of the present invention can be widely used as an active ingredient for therapeutic agents, animal feeds or drinking water, cleaners and sanitizers for preventing and treating the infectious diseases caused by Salmonella enteritidis, Salmonella typhimurium, Salmonella gallinarum or Salmonella pullorum including salmonellosis, Salmonella food poisoning, Fowl Typhoid, and Pullorum disease or for controlling the Salmonella bacteria.